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A B S T R A C T
This paper addresses the modification of poly(dimethylsiloxane), i.e. PDMS, using plasma surface treatment and
a novel application of the membrane created. A set of model compounds were analysed to determine their per-
meation through PDMS both with, and without, plasma treatment. It was found that plasma treatment reduced
permeation for the majority of compounds yet had little effect for some compounds, such as caffeine, with results
indicating that polarity plays an important role in permeation, as is seen in human skin. Most importantly, a di-
rect correlation was observed between plasma-modified permeation data and literature data through calculation
of membrane permeability (K⁠p) values implying plasma-modified silicone membrane (PMSM) could be consid-
ered a suitable in vivo replacement to predict clinical skin permeation.
1. Introduction
Poly(dimethylsiloxane), also known as PDMS, is a commonly used
polymer based on its favourable properties including transparency, gas
permeability and general high level of stability [1]. The basic structure
of the polymer is composed of –O–Si(CH⁠3)⁠2 – units which can be manu-
factured to a variety of specific requirements depending upon the con-
straints of the application, i.e. several types are available with specific
functions [2]. The extensive range of uses of PDMS includes air separa-
tion [3,4], environmental control [5], separation of liquid mixtures [6],
wound dressings and medical applications [7,8], microfluidics [9–11]
and biochemical sensing [12]. As a result of such a diverse, and exten-
sive, breadth of functionalities a substantial amount of literature can be
found on the properties of PDMS (see previous references) or, for exam-
ple, the dependence of gas permeability on membrane thickness (thus
requiring reliable preparation techniques) [13].
As expected, researchers have attempted to modify the surface of
PDMS to enhance its suitability, particularly in the field of microflu-
idics. This is because biological samples easily and strongly interact with
PDMS surfaces because of the inherent hydrophobicity of the material
which has led to numerous applications of modified PDMS surfaces in
biological assays, such as biomolecule separation, immunoassay [14],
cell culture and DNA hybridisation [15].
One particularly interesting modification to standard PDMS that has
been the subject of investigation in recent years is modification of the
surface using plasma treatment. It is generally accepted that PDMS
(upon exposure to plasma) develops silanol groups (–OH) at the expense
of methyl groups (–CH⁠3) [16,17] as a result of oxidation of the surface
layer [18]. This creates a more highly hydrophilic surface which can be
observed through a reduction in the contact angle of water [19] and
may cause a wrinkling effect under certain conditions [20]. As a conse-
quence of this transformation, the properties of the membrane are trans
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formed. For example, it has been reported that freshly oxidised PDMS
showed a significantly smaller gas diffusion coefficient compared with
untreated membrane [21]. In some studies the process of plasma surface
treatment is the first step in a series of procedures to modify the sur-
face, i.e. to create a variety of more complex products that have different
properties to the original PDMS or to avoid certain disadvantages. For
example, following plasma treatment it is possible to immerse the mem-
brane in acrylic acid, then immobilise with chitosan and gelatin and
finally culture fibroblast cells onto the surface to enhance cell growth
[22]. Other compounds have also been incorporated onto the surface
of plasma treated PDMS, for example self-assembled amphipathic film,
to address nonspecific protein adsorption issues thus broadening the
potential uses of PDMS-based microfluidic chips in complex biological
analysis [23].
There is one area of analytical research that utilises PDMS yet has
not previously considered plasma treated surface modification, namely
the use of PDMS to determine the permeation of pharmaceutical com-
pounds for the prediction of skin permeability [24]. Traditionally, such
permeation studies utilise human or, more frequently animal, skin
whereby the amount of a compound is monitored over a period of time
as it permeates across the skin layer from a donor to receiver phase
[25]. This data is essential for a large variety of chemicals where there
is the likelihood they will, at some point, come into contact with human
skin, such as cosmetics, pharmaceuticals and household products. In re-
cent years PDMS has been proposed as an ethical, economic and reliable
alternative for the determination of compound permeation along with
several other techniques [26]. For example, when permeation of differ-
ent vehicles was considered, a trend between flux values for the model
membrane and skin was evident suggesting that silicone membrane may
provide information on qualitative trends [27]. This is particularly use-
ful for compounds intended for use in cosmetic products where the use
of animal testing within the EU and several other countries is no longer
an option. However, it has been found that the data generated does not
always directly relate to in vivo data and can be affected by a variety
of factors, such as the presence of surfactants [28,29]. In the current
work we consider the impact on permeation for a set of model com-
pounds following transformation of the hydrophobic surface of PDMS
using plasma surface treatment with the intention to create a more hy-
drophilic (i.e. more skin-like [30]), and therefore potentially more suit-
able, in vitro model.
2. Experimental
2.1. Plasma surface treatment method
Polydimethylsiloxane (PDMS) sheets (Silatos™) were used as pur-
chased from ATOS, Sweden (150 × 200 × 0.13 mm). Disks were cut
with a diameter of 14 mm and placed in a benchtop laboratory plasma
unit (Henniker Scientific) under low pressure on full power (40 kHz,
100 W), this was then repeated on the alternate surface under identi-
cal conditions with both surfaces exposed for 90 s each (based on the
knowledge that a more prolonged exposure time can result in cracking
[31]). Contact angle analysis and permeation studies were performed
immediately (within one hour) after plasma treatment to avoid storage
stability issues. To examine the stability of the plasma-treated PDMS
membrane, permeation analysis of a model compound (lidocaine) was
performed through freshly treated and aged membrane. Results implied
the membrane retained its hydrophilic surface even after eight weeks
of storage (data not shown), implying stability was not an issue in this
study. Furthermore, polar solvents, such as those used in this study, are
known to enhance the stability of plasma-treated membranes thus en-
suring stability was not an issue in this work.
2.2. Contact angle analysis
The static contact angle of the untreated and treated PDMS samples
was measured by the sessile drop method using an optical goniometer
with attached precision syringe (FTA1000, Surface Science Instruments,
USA). A drop of deionised water was dispensed from the syringe onto
the freshly treated PDMS surface below. A minimum of three measure-
ments were taken for each sample from different locations on the sur-
face to determine an average value.
2.3. Permeation studies
Sixteen model compounds were analysed using a Franz-type, be-
spoke, diffusion cell system with a diffusional area of 0.64 cm⁠2:
aminopyrine (Fisher Scientific, Loughborough, UK, ≥ 97%), benzoic
acid (Sigma Aldrich, Dorset, UK, ≥ 99.5%), caffeine (Sigma Aldrich,
Dorset, UK, ≥ 99%), ethyl 4-hydroxybenzoate (Sigma Aldrich, Dorset,
UK, ≥ 99%), ethyl 4-aminobenzoate (Sigma Aldrich, Dorset, UK, >
98%), ibuprofen (BASF, ≥ 99%), lidocaine (Sigma Aldrich, Dorset, UK,
≥ 98%), methyl 4-hydroxybenzoate (Sigma Aldrich, Dorset, UK, ≥
98%), methyl 4-aminobenzoate (Sigma Aldrich, Dorset, UK,
≥98%), propyl 4-hydroxybenzoate (Sigma Aldrich, Dorset, UK, ≥ 99%),
propyl 4-aminobenzoate (Alfa Aesar, Lancashire, UK, 98%), Flurbipro-
fen ( okyo Chemical Industry Ltd, > 98%), Diclofenac (Tokyo Chem-
ical Industry Ltd, > 98%), Ketoprofen (Tokyo Chemicals Industry Ltd,
> 98%) acetyl salicylic acid (Sigma Aldrich, Dorset, UK, ≥ 99%) and
salicylic acid (Sigma Aldrich, Dorset, UK, ≥ 99.5%), all as saturated so-
lutions placed in the donor phase. In all cases samples were analysed
using a UV spectrophotometer (Agilent Technologies, UK) to determine
concentrations at a suitable wavelength for each drug.
Donor and receiver phases consisted of sonicated 0.05 M pH 7.4
phosphate buffered saline (K⁠2HPO⁠4, Sigma Aldrich, Dorset, UK, KH⁠2PO⁠4,
Sigma Aldrich, Dorset, UK and NaCl, Fisher Scientific Ltd., Lough-
borough, UK) and an experimental temperature of 32 °C. Cells were
stirred and left to equilibrate for 30 min, i.e. the equilibration pe-
riod receptor phase remained as the starting experimental receptor
phase solution. 0.6 mL samples were extracted from the 1.5 mL re-
ceptor phase every 45 min and replaced with fresh buffer for a to-
tal of 6 h. K⁠p values were then calculated using all data points for
all compounds from t=0 except in the case of caffeine where an ini-
tial lag period of 60 min was discarded from calculation as a result
of the comparatively low extent of permeation. Upon addition of com-
pound to the donor phase the buffer was unable to maintain the orig-
inal pH and so the pH was measured for each resultant solution to
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Solubility data required for analysis is presented in Table S1
(Supplementary information).
3. Results and discussion
3.1. Surface hydrophobicity
PDMS is renowned for its hydrophobic nature with typical static wa-
ter contact angle (WCA) measurements in the region of ≥ 100° [19].
Water contact angles were measured for PDMS as received and then
again after plasma treatment. Prior to treatment the average WCA was
found to be 112.3° (± 0.9) whereas after plasma treatment the con-
tact angle had reduced to an average of 60.7° (± 5.1). This result con-
firms that the plasma treatment process had significantly reduced the
hydrophobicity of the surface, as expected based on previous literature
[32].
3.2. Permeation analysis
3.2.1. Effect of surface treatment on permeation
As can be seen in Fig. 1, pre-treatment of the silicone membrane
used in the permeation analysis results in a significant reduction in cu-
mulative amount permeated over a 6 h period for benzoic acid. This
confirms that even though it is only the surface of the silicone that has
been modified through the plasma treatment, the effect on the overall
properties of the membrane is significant. This result presents the first
reported evidence that plasma treatment on silicone membrane can af-
fect the permeation of pharmaceutical compounds which is an impor-
tant finding based on the fact that permeation studies are often used
when analysing pharmaceutical compounds.
Interestingly, across the range of compounds analysed, the degree to
which plasma treatment altered the permeability profile varied some-
what. As previously mentioned, the cumulative amount of benzoic acid
permeated was dramatically reduced by replacing standard membrane
with plasma treated membrane. This considerable effect was also ob-
served for several other compounds, for example, ibuprofen, lidocaine
and aminopyrine. In contrast, several compounds did not exhibit a
dramatic reduction in permeation using membrane pre-treated with
plasma, as exemplified in Fig. 2 with caffeine. Other compounds for
which perme
Fig. 1. Cumulative amount permeated for benzoic acid using (▲) unmodified silicone
membrane and (■) plasma surface treated silicone membrane. n = 3, ± = SD.
Fig. 2. Cumulative amount permeated for caffeine using (▲) unmodified silicone mem-
brane and (■) plasma surface treated silicone membrane. n = 3, ± = SD.
ation was not dramatically reduced by replacement with plasma treated
membrane included ethyl 4-aminobenzoate and diclofenac.
As it was found experimentally that different compounds resulted
in different total amounts permeated, both with standard, unmodified
membrane and plasma treated membrane, the data was simplified to al-
low a clearer interpretation to be made. This was achieved by consider-
ing the total cumulative amount permeated using plasma treated mem-
brane as a percentage of the total cumulative amount permeated using
standard, unmodified membrane. A summary of the values (after a total
experimental time of six hours) can be seen in Table 1.
Based on the data in Table 1 it can be seen that the most significant
reduction in permeation was generally observed for compounds with
the lower polar surface areas. These findings indicate that polarity plays
an important role in permeation, as is seen in biological systems such as
intestinal absorption [33], blood-brain barrier permeation [34] and hu-
man skin permeation. Based on previous work, transdermal penetration
has been linked with structural predictors, such as polar surface area
whereby the usefulness of such parameters has been assessed [35]. It
would appear that our plasma treated membrane findings fit well with
published literature [36], as illustrated in Fig. 3, and that treatment has
an impact on the permeation of a set of compounds to varying extents
which can be linked to polar surface area (R⁠2 = −0.73, values for PSA
derived using Chemspider (www.chemspider.com)).
Assuming that the surface of the membrane has a negative charge
overall, the more water soluble compounds (which may have a dipolar
effect) were removed from the dataset and the linearity reconsidered. It
was found that there was no change in the linearity of the data after the
removal of the more hydrophilic compounds. Furthermore, analysis was
undertaken to consider if logD, molecular weight or hydrogen bonding
were related to the reduction in permeation and no significant relation-
ships were observed (data not shown). In addition, Table 1 shows that
polar surface area is not directly related to the amount permeated, ei-
ther unmodified or plasma treated, confirming it is the change in perme-
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Table 1
Total cumulative amount of compound permeated after 6 h through unmodified and plasma treated membrane, also expressed as a percentage reduction (%). Polar surface area (PSA)
values were calculated using Chemspider (www.chemspider.com).
Compound Amount permeated (μg/cm⁠2)
Unmodified Plasma treated Reduction (%) PSA (Å⁠2)
Acetyl salicylic acid 561.1 432.1 23.00 64
Aminopyrine 3360.5 1727.7 48.59 27
Benzoic acid 3507.5 1893.8 46.01 37
Caffeine 58.92 66.73 −13.27 58
Diclofenac 41.11 38.50 6.351 49
Ethyl 4-aminobenzoate 1519.56 1543.58 −1.581 52
Ethyl 4-hydroxybenzoate 782.8 631.8 19.29 47
Flurbiprofen 345.0 279.7 18.93 37
Ibuprofen 1916.6 868.0 54.71 37
Ketoprofen 118.1 96.03 18.93 54
Lidocaine 4911.4 2819.24 42.60 36
Methyl 4-aminobenzoate 2346.51 1760.04 24.99 52
Methyl 4-hydroxybenzoate 818.76 601.5 26.53 47
Propyl 4-aminobenzoate 1495.01 1473.85 1.415 52
Propyl 4-hydroxybenzoate 679.76 425.15 37.46 47
Salicylic acid 1841.8 1437.4 21.96 58
Butyl 4-aminobenzoate 901.1 714.1 20.75 52
Butyl 4-hydroxybenzoate 782.4 652.1 16.66 47
Fig. 3. Reduction in the cumulative amount permeated using silicone membrane to high-
light the importance of polar surface area (PSA).
3.2.2. Suitability of plasma treated silicone to predict in vivo skin
membrane permeability
Membrane permeability (K⁠p) is frequently considered when inves-
tigating the behaviour of compounds through skin for inter-labora-
tory studies, although it should be noted that maximum flux is some-
times considered for individual studies [37]. Skin permeability may
be characterised by both steady state flux and permeability coeffi-
cient, and whilst steady state flux appears more practical from a clin-
ical perspective as it can be used readily to evaluate the use of de-
livery devices, it does not allow for the normalisation of concentra-
tion and therefore hinders inter-penetrant comparisons. Furthermore,
significant quantities of permeability data have been published in the
form of permeability coefficients, for example the large collection of
skin permeability data published by Flynn [38] which allows for com-
parative analysis such as this work to be undertaken. Researchers
have attempted to simplify the prediction of K⁠p to aid in the develop-
ment of formulations using a variety of in vitro systems (for example
[39] and [40]), mainly with the aims of either avoiding the use of an-
imal testing or for economic reasons [26]. An ideal skin mimic system
will result in K⁠p values that correlate well with literature. Permeability
data acquired during this study is presented in Table 2 for both standard
PDMS membrane and plasma-treated membrane for a set of compounds.
These are presented along with literature values [41–45] which were
selected based on their similarity to the experimental conditions used
during this study.
Membrane permeability values using standard membrane (for com-
parison) and then using plasma pre-treated membrane were calculated
and compared with literature data (Figs. 4 and 5). Using standard PDMS
membrane produced a partially linear relationship between experimen-
tal and literature data (R⁠2= 0.77). Although this will allow some pre-
diction of permeability, it cannot be considered a close enough fit to
be confident in predicting data for compounds beyond those considered
in this study. However, if the PDMS membrane is firstly plasma treated
and then used for analysis with the same set of compounds, the linear-
ity increases significantly with an R⁠2= 0.88. This method offers an im-
proved system using plasma-treated membrane for permeability analy-
sis and would provide an enhanced experimental in vitro system for pre-
dictive purposes.
Membrane permeability (K⁠p) is constant for a particular compound
and is a reflection of the ability to cross the membrane, normalised by
concentration. In an ideal situation, a compound should always pro-
vide an identical value, regardless of vehicle formulation based on the
assumption that the compound does not interact with the formulation
components. In this case, a slightly different scenario is presented in that
different K⁠p values were observed for a compound with identical for-
mulations yet different membrane properties. This finding implies there
must be an interaction between the membrane itself and the compound
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Table 2
Experimental membrane permeability (K⁠p) values (× 10⁠−4) for both standard PDMS membrane and plasma-treated membrane, presented alongside literature permeability data [41–45].
All results are expressed as the mean ± S.D. (n = 3).
Chemical Membrane permeability (Kp) × 10⁠−4 (cm/min)
Standard PDMS Plasma-treated PDMS Literature
Acetyl salicylic acid 1.255 ± 0.051 0.9821 ± 0.0709 0.085 [41]
Aminopyrine 2.01 ± 0.11 1.075 ± 0.139 0.198 [42]
Benzoic Acid 11.38 ± 0.40 6.236 ± 0.428 2.94 [43]
Caffeine 0.08840 ± 0.00440 0.1026 ± 0.0120 0.108 [42]
Diclofenac 0.6099 ± 0.0316 0.5618 ± 0.0272 0.167 [44]
Ethyl 4-aminobenzoate 47.83 ± 1.56 49.35 ± 0.98 121 [42].
Ethyl 4-hydroxybenzoate 18.40 ± 0.47 15.00 ± 1.03 2.32 [42]
Flurbiprofen 2.169 ± 0.063 1.767 ± 0.126 0.379 [43]
Ibuprofen 11.91 ± 0.54 5.432 ± 0.514 0.56 [43]
Ketoprofen 0.3557 ± 0.0193 0.2944 ± 0.0126 1.17 [43]
Lidocaine 36.11 ± 1.54 22.98 ± 1.09 4.209 [45]
Methyl 4-aminobenzoate 36.45 ± 2.54 27.80 ± 2.31 11.04 [42]
Methyl 4-hydroxybenzoate 7.092 ± 0.363 5.698 ± 0.359 1.49 [42]
Propyl 4-hydroxybenzoate 39.43 ± 0.62 26.17 ± 1.65 2.18 [42]
Propyl 4-aminobenzoate 55.04 ± 1.75 55.31 ± 2.27 134 [42].
Salicylic Acid 6.560 ± 0.359 5.158 ± 0.142 2.30 [44]
Butyl 4-aminobenzoate 109.9 ± 5.8 89.21 ± 7.61 121 [38].
Butyl 4-hydroxybenzoate 71.21 ± 3.28 60.94 ± 3.91 16.62 [38]
Fig. 4. Relationship between experimental K⁠p values (standard membrane) and literature
K⁠p values (R⁠2 = 0.77).
4. Conclusions
In summary, this study presents the first attempt to modify PDMS
membrane using plasma treatment to determine the subsequent effect
on permeability analysis. It can be seen that it is possible to modify the
permeability of compounds through the membrane and the extent of the
effect is dependent upon the polar surface area of the permeating mole-
cule. Furthermore, plasma-treated membrane is a more suitable system
for the in vitro analysis of compounds as it has been found to correlate
more closely with literature data compared with standard PDMS mem-
brane.
5. Summary
Predicting the permeation of compounds through skin is currently
one of the biggest obstacles in replacing the use
Fig. 5. Relationship between experimental K⁠p values (plasma-treated membrane) and lit-
erature K⁠p values (R⁠2= 0.88).
of animals in pharmaceutical analysis. Although PDMS has shown some
promise as a skin mimic, the results did not match literature data closely
enough for it to be deemed a suitable alternative. This paper considers
modification of the membrane using plasma treatment which was then
tested with a set of compounds and found to closely match literature
data from established in vivo systems. Thus, proving that modified PDMS
is a suitable skin mimic for the pharmaceutical industry to adopt to re-
place current systems.
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Appendix A. Supporting information
Supplementary data associated with this article can be found in the
online version at doi:10.1016/j.jpha.2017.05.003.
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